Gloucester Reports Positive Results From Phase IIb Lymphoma Registration Trial
Posted on: Monday, 9 June 2008, 09:01 CDT
Gloucester Pharmaceuticals has reported positive data from a Phase IIb registration trial of romidepsin in patients with cutaneous T-cell lymphoma.
GPI-04-0001 is a Phase IIb, non-randomized, open-label, single-arm international, multi-center registration study designed to evaluate the efficacy, safety and tolerability of romidepsin as a treatment for cutaneous T-cell lymphoma (CTCL).
The primary endpoint of the registration trial, objective disease response rate (ORR) in patients who had failed previous therapy, was achieved with an ORR of 40.3% (29/72 of evaluable patients). Approximately 33.3% (24/72) of patients experienced a partial response (PR) and 6.9% (5/72) of patients achieved a complete response (CR).
The ORR in patients with advanced stage disease (IIB-IVA) was 47.9% (23/48). Approximately 37.5% (18/48) experienced a PR and 10.4% (5/48) experienced a CR. Additionally, 92.3% (48/52) of patients with pruritus (intense itching) at the outset of the trial had some relief from their pruritus.
Secondary endpoints, including duration of response, time to response and time to progression, continue to mature and will be announced later, the company said.
Jean Nichols, president and COO of Gloucester, said: "These data will be central to Gloucester's new drug application for romidepsin in CTCL and we continue to be pleased with the results as they mature."
Source: Datamonitor
Related Articles
- American Heart Association Late-Breaking Clinical Trial Report: Tailoring Drug Dose to Heart Failure Patients' Response More Effective
- Curemark Enrolls First Patients in Phase III Clinical Trials for Autism Treatment
- Boston Scientific Data Show Real-World Survival Rates for Implantable Cardiac Device Patients Exceed Rates From Clinical Trials
- Intrasphere Technologies Releases Version 1.5 of Its PharmaCM Clinical Trial Registration Solution Powered by Microsoft
- ThromboGenics Completes Patient Enrolment for Phase II Trial of Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME)
- Moberg Begins Recruiting Patients for Phase III Dermatitis Trial
- Pro-Pharmaceuticals Begins Patient Dosing for Biliary Cancer Trial
- Heartscape Enrolls First Patient in OCCULT-MI Clinical Trial Using Its PRIME ECG(R) System
- ImClone Systems Commences Patient Treatment in U.S. Phase I Clinical Trial Of IMC-1121B
- Orlistat Augments Postprandial Increases in Glucagon-Like Peptide-1 in Obese Type 2 Diabetic Patients: Response to Damci Et Al./ Orlistat Augments Postprandial Increases In Glucagon-Like Peptide-1 in Obese Type 2 Diabetic Patients: Response to Horowitz Et
 |
 |
User Comments (0)
RSS Feeds